Day One Biopharma 将以高达 $285M 的价格收购 Mersana Therapeutics，以扩大其抗癌药物管线。 Day One Biopharma to acquire Mersana Therapeutics for up to $285M to boost its cancer drug pipeline.

第一天,生物制药商同意以价值达2.85亿美元的交易购买Mersana治疗药品,包括预付每股25美元现金付款和可能按里程碑支付的每股30.25美元。 Day One Biopharmaceuticals agreed to acquire Mersana Therapeutics in a deal worth up to $285 million, including an upfront $25 per share cash payment and potential milestone-based payments of up to $30.25 per share. 该收购正在等待监管机构和股东的批准,旨在扩大Day One的瘤管道,特别是在儿科癌症中,并整合Mersana的抗体-药物结合体平台和临床阶段候选药物. The acquisition, pending regulatory and shareholder approval, aims to expand Day One’s oncology pipeline, particularly in pediatric cancers, and integrate Mersana’s antibody-drug conjugate platform and clinical-stage candidates. Merasana的主要药物Emi-Le是一个重点。 Mersana’s lead drug, Emi-Le, is a key focus. 第1天报告其主要药物Tvorafenib在第三季度销售量强劲,收入增至3 850万美元,处方增加了18%的四分之一。 Day One reported strong third-quarter sales of its lead drug, tovorafenib, with revenue rising to $38.5 million and prescriptions increasing 18% quarter-over-quarter. 该公司在2025年将tvorafenib的2025年收入预测提高到1.45亿至1.5亿美元,以4.516亿美元的现金结束本季度。 The company raised its 2025 revenue forecast for tovorafenib to $145–$150 million and ended the quarter with $451.6 million in cash. 预计招标将在2025年11月12日的10个工作日内开始。 The tender offer is expected to begin within 10 business days of November 12, 2025.